' Watch and Wait' Feasible for Some Rectal Cancer Patients

TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Purpose: Neoadjuvant chemoradiation followed by surgery is the current standard of care in the treatment of locally advanced rectal cancer. Those who achieved pathologic complete response, following this standard of care, complete pathologic response (pCR) had better outcome. Until now there are no reliable clinical parameters to predict this response. The purpose of the study was to evaluate whether tumor volume may serve as a predictive factor in patients treated with neoadjuvant chemoradiotherapy. Materials and Methods: Between September 2015 and September 2019, patients diagnosed with stage IIA to IIIC recta...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
ConclusionAbdominopelvic actinomycosis is a rare pathology and has therefore rarely been dealt with. This issue can lead to unnecessary and mutilating surgery. We report an exceptional coincidence of rectal adenocarcinoma and mesorectal actinomycosis mistaken for mesorectal extension of the cancer.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Clin Colorectal Cancer. 2021 Jun 26:S1533-0028(21)00064-5. doi: 10.1016/j.clcc.2021.06.004. Online ahead of print.ABSTRACTPURPOSE: To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.METHODS: Individual patient data of LARC patients from 3 prospective clinical trials was analyzed. Neoadjuvant treatment regimens comprised chemoradiotherapy (CRT) with fluorouracil (5-FU) or mFOLFOX6, neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI. The postoperative pathological result, local recurrence and disease-fr...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Oxaliplatin-based adjuvant chemotherapy is not associated with improved survival outcomes compared with fluoropyrimidine-only chemotherapy in this real-world study.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
ConclusionsThere was no observed benefit of chronomodulated radiotherapy in our cohort of rectal cancer patients. Review of the literature and meta-analysis confirms the benefit of delayed surgery, with a plateau in complete response rates at approximately 60-days between completion of radiotherapy and surgery. In our cohort, time to surgery for the majority of our patients lay along this plateau and this may be a more dominant factor in determining response to neoadjuvant therapy, obscuring any effects of chronomodulation on tumour response. We would recommend surgery be performed between 8 and 11 weeks after completion o...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
Adv Cancer Res. 2021;151:39-67. doi: 10.1016/bs.acr.2021.02.003. Epub 2021 Apr 9.ABSTRACTMulti-modal treatment of non-metastatic locally advanced rectal adenocarcinoma (LARC) includes chemotherapy, radiation, and life-altering surgery. Although highly effective for local cancer control, metastatic failure remains significant and drives rectal cancer-related mortality. A consistent observation of this tri-modality treatment paradigm is that histologic response of the primary tumor to neoadjuvant treatment(s), which varies across patients, predicts overall oncologic outcome. In this chapter, we will examine this treatment re...
Source: Advances in Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals | Rectal Cancers | Study